Literature DB >> 23607617

Kidney transplantation down-regulates expression of organic cation transporters, which translocate β-blockers and fluoroquinolones.

Giuliano Ciarimboli1, Rita Schröter, Ute Neugebauer, Beate Vollenbröker, Gert Gabriëls, Hrvoje Brzica, Ivan Sabolić, Gesine Pietig, Hermann Pavenstädt, Eberhard Schlatter, Bayram Edemir.   

Abstract

Kidney transplanted patients are often treated with immunosuppressive, antihypertensive, and antibiotic drugs such as cyclosporine A (CsA), β-blockers, and fluoroquinolones, respectively. Organic cation transporters (OCT) expressed in the basolateral membrane of proximal tubules represent an important drug excretion route. In this work, the renal expression of OCT after syngeneic and allogeneic kidney transplantation in rats with or without CsA immunosuppression was studied. Moreover, the interactions of CsA, β-blockers (pindolol/atenolol), and fluoroquinolones (ofloxacin/norfloxacin) with rOCT1, rOCT2, hOCT1, and hOCT2 in stably transfected HEK293-cells were studied. Kidney transplantation was associated with reduced expression of rOCT1, while rOCT2 showed only reduced expression after allogeneic transplantation. All drugs interacted subtype- and species-dependently with OCT. However, only atenolol, pindolol, and ofloxacin were transported by hOCT2, the main OCT in human kidneys. While CsA is not an OCT substrate, it exerts a short-term effect on OCT activity, changing their affinity for some substrates. In conclusion, appropriate drug dosing in transplanted patients is difficult partly because OCT are down-regulated and because concomitant CsA treatment may influence the affinity of the transporters. Moreover, drug-drug competition at the transporter can also alter drug excretion rate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607617     DOI: 10.1021/mp4000234

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.

Authors:  Jia Yin; Haichuan Duan; Yoshiyuki Shirasaka; Bhagwat Prasad; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2015-09-15       Impact factor: 3.922

2.  Mouse organic cation transporter 1 determines properties and regulation of basolateral organic cation transport in renal proximal tubules.

Authors:  Eberhard Schlatter; Philipp Klassen; Vivian Massmann; Svenja K Holle; Denise Guckel; Bayram Edemir; Hermann Pavenstädt; Giuliano Ciarimboli
Journal:  Pflugers Arch       Date:  2014-08       Impact factor: 3.657

3.  Revisiting atenolol as a low passive permeability marker.

Authors:  Xiaomei Chen; Tim Slättengren; Elizabeth C M de Lange; David E Smith; Margareta Hammarlund-Udenaes
Journal:  Fluids Barriers CNS       Date:  2017-10-31

Review 4.  Regulation Mechanisms of Expression and Function of Organic Cation Transporter 1.

Authors:  Giuliano Ciarimboli
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

Review 5.  Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking.

Authors:  Wei Zou; Birui Shi; Ting Zeng; Yan Zhang; Baolin Huang; Bo Ouyang; Zheng Cai; Menghua Liu
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

Review 6.  Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.

Authors:  Elisa Lozano; Elisa Herraez; Oscar Briz; Virginia S Robledo; Jorge Hernandez-Iglesias; Ana Gonzalez-Hernandez; Jose J G Marin
Journal:  Biomed Res Int       Date:  2013-07-31       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.